Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
|Videos|January 20, 2022
How appropriate use criteria was created for PSMA-PET imaging
Author(s)Urology Times staff
“There is a rather extensive process of how to develop appropriate use criteria. It is primarily based on literature and evidence, systematic reviews, and analysis of those data,” says Hossein Jadvar, MD, PhD.
Advertisement
In this video, Hossein Jadvar, MD, PhD, discusses the process for creating the appropriate use criteria for prostate-specific membrane antigen (PSMA) PET imaging that was recently released in the
Advertisement
Related to this article
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how work force gaps may affect comprehensive infertility evaluations.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Advertisement
Advertisement
Trending on Urology Times
1
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
2
Infertility care: Examining geographic gaps in access
3
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
4
Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide
5